While elevated SphK2 has contrasting roles in cancers of different types (211), as discussed in detail below in section 7, inhibition of SphK2 synergizes with PI drugs to kill MM cells and can re-sensitize resistance MM cells (208, 212). Here, SPHK2 is linked to Miyoshi myopathy.